Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: Clinical significance and therapeutic implications

Leukemia

Volumn 17, Issue 8, 2003, Pages 1437-1447

  Carew, J S ^a   Zhou, Y ^a   Albitar, M ^a   Carew, J D ^b,c   Keating, M J ^a   Huang, Peng ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Chemotherapy; Chronic lymphocytic leukemia; Mitochondria; Mutation; Reactive oxygen species

Indexed keywords

ALKYLATING AGENT; CELL NUCLEUS DNA; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME C OXIDASE; ESTRADIOL 3 METHYL ETHER; FLUDARABINE; HISTONE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA DETERMINATION; DNA POLYMORPHISM; DNA REPAIR; DRUG EFFECT; GENE MUTATION; HETEROPLASMY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; RESPIRATORY CHAIN; TREATMENT OUTCOME;

EID: 0043029566     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403043     Document Type: Article

References (38)

1. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999;283:1482-1488.
2. Rasmussen LJ, Singh KK. Genetic integrity of the mitochondrial genome. In: Singh KK (ed). Mitochondrial DNA Mutations in Aging, Disease, and Cancer. New York, NY: Springer, 1998, pp 115-127.
3. Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1992; 61: 1175-1212.
4. Carew JS, Mitochondrial defects in cancer. Mol Cancer 2002; 1: 9.
5. Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res 1995; 9: 1005-1013.
6. Huang P, Feng L, Oldham, EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
7. Levin BC, Cheng H, Reeder DJ. A human mitochondrial DNA standard reference material for quality control in forensic identification, medical diagnosis and mutation detection. Genomics 1999; 55: 135-146.
8. Wei YH, Kao SH, Lee HC. Simultaneous increase of mitochondrial DNA deletions and lipid peroxidation in human aging. Ann NY Acad Sci 1996; 786: 24-43.
9. Talarico T, Cullinan CM, Gray PJ, Webster LK, Deacon GB, Phillips DR. Nuclear and mitochondrial distribution of organoamidoplatinum(II) lesions in cisplatin-sensitive and resistant adenocarcinoma cells. Anticancer Drug Des 2001; 16: 135-141.
10. Olivero OA, Chang PK, Lopez-Larraza DM, Semino-Mora MC, Poirier MC. Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. Mutat Res 1997; 391: 79-86.
11. Sanchez-Cespedes M, Parrella P, Nomoto S, Cohen D, Xiao Y, Esteller M et al. Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res 2001; 61: 7015-7019.
12. Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D. Mitochondrial D-loop mutations as clonal markers in multi-centric hepatocellular carcinoma and plasma. Clin Cancer Res 2002; 8: 481-487.
13. Miyazono F, Schneider PM, Metzger R, Warnecke-Eberz U, Baldus SE, Dienes HP et al. Mutations in the mitochondrial DNA D-Loop region occur frequently in adenocarcinoma of Barrett's esophagus. Oncogene 2002; 21: 3780-3783.
14. Reynier P, Malthiery Y. Accumulation of deletions in MtDNA during tissue aging: analysis by long PCR. Biochem Biophys Res Commun 1995; 217: 59-67.
15. Kajander OA, Karhunen PJ, Jacobs HT. The relationship between somatic mtDNA rearrangements, human heart disease and aging. Hum Mol Genet 2002; 11: 317-324.
16. Richardson ME, Siemann DW. DNA damage in, cyclophosphamide-resistant tumor cells: the role of glutathione. Cancer Res 1995; 55: 1691-1695.
17. Berger MR, Bedford P, Zeller WJ, Kaufmann M. A comparative study of therapeutic activity, myelotoxicity and DNA damage i n the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide). Invest New Drugs 1984; 2: 181-186.
18. Ford CD, Warnick CT. DNA damage and repair in patients receiving high-dose cyclophosphamide and radiation. NCI Monogr 1988: 41-44.
19. Chatterjee R, Haines GA, Perera DM, Goldstone A, Morris ID. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum Reprod 2000; 15: 762-766.
20. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36: 181-188.
21. Huang P, Siciliano MJ, Plunkett W. Gene deletion, a mechanism of induced mutation by arabinosyl nucleosides. Mutat Res 1989; 210: 291-301.
22. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314.
23. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003.
24. Ha PK, Tong BC, Westra WH, Sanchez-Cespedes M, Parrella P, Zahurak M et al. Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clin Cancer Res 2002; 8: 2260-2265.
25. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD et al. Somatic mutations of the mitochondrial genome in human colorectal tumors. Nat Genet 1998; 20: 291-293.
26. Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000; 287: 2017-2019.
27. Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-Jimenez P, Thrilly WG. High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat Genet 2001; 28: 147-150.
28. Coskun PE, Ruiz-Pesini E, Wallace DC. Control region mtDNA variants: Longevity, climatic adaptation, and a forensic conundrum. Proc Natl Acad Sci USA 2003; 100: 2174-2176.
29. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-2933.
30. Liu SL, Lin X, Shi DY, Cheng J, Wu CQ, Zhang YD. Reactive oxygen species stimulate human hepatoma cell proliferation via cross-talk between PI3K/PKB and JNK signaling pathways. Arch Biochem Biophys 2002; 406: 173-182.
31. Haddad JJ. Redox regulation of pro-inflammatory cytokines and IkappaB-alpha/NF-kappaB nuclear translocation and activation. Biochem Biophys Res Commun 2002; 296: 847-856.
32. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414: 265-266.
33. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J. Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis alpha-induced apoptosis. J Exp Med 1998; 188: 211-216.
34. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999; 106: 995-1004.
35. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105: 752-757.
36. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77: 1103-1107.
37. Wood L, Lesse MR, Leblond B, Woo LW, Ganeshapillai D, Purohit A et al. Inhibition of superoxide dismutase by 2-methoxyoestradiol analagues and oestrogen derivatives: structure-activity relationships. Anticancer Drug Des 2001; 16: 209-215.
38. Golab J, Nowis D, Skrzycki M, Czeczot H, Baranczyk-Kuzma A, Wilczynski GM et al. Anti-tumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol, a superoxide dismutase inhibitor. J Biol Chem 2002; 278: 407-414.